Inicio › Mieloma múltiple › Florida › Miami
Ensayos clínicos de Mieloma múltiple en Miami, FL
22 estudios para Mieloma múltiple buscan participantes en centros de Miami y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
ReclutandoFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- y 3 más
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- University of Miami Hospital, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutandoFase 1
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutandoFase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
ReclutandoFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center Kendall, Miami
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
ReclutandoFase 1/2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutandoFase 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutandoFase 1/2
- Research Site, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- y 2 más
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
ReclutandoFase 2
- University of Miami, Miami
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
ReclutandoFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
ReclutandoFase 2
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
ReclutandoFase 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Reclutando
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
ReclutandoEstudio observacional
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
ReclutandoFase 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
ReclutandoFase 2
- University of Miami, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
ReclutandoFase 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY59 estudios
- Boston, MA45 estudios
- Atlanta, GA42 estudios
- Houston, TX39 estudios
- Durham, NC36 estudios
- Nashville, TN31 estudios
- Denver, CO26 estudios
- St. Louis, MO26 estudios
- Rochester, MN25 estudios
- Columbus, OH25 estudios
- Chicago, IL24 estudios
- Milwaukee, WI23 estudios
Otros estudios en Miami
- Cáncer de seno42 estudios
- Cáncer (todos los tipos)36 estudios
- Cáncer de pulmón de células no pequeñas35 estudios
- Cáncer de próstata30 estudios
- Obesidad28 estudios
- Cáncer de ovario24 estudios
- Leucemia mielógena aguda24 estudios
- Sobrepeso23 estudios
- Cáncer metastásico22 estudios
- Cáncer de pulmón22 estudios
- Enfermedad de Alzheimer21 estudios
- Enfermedad de obstrucción pulmonar crónica20 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.